Page 44 - Demo

32. Ma C, Peng Y, Li H, et al. Organ-on-a-Chip: ANew Paradigm for Drug Development. TrendsPharmacol Sci 2021; 42: 119-33.https://doi.org/10.1016/j.tips.2020.11.009.33. Cacciamali A, Villa R, Dotti S. 3D Cell Cultures:Evolution of an Ancient Tool for NewApplications. Front Physiol 2022; 13: 836480.https://doi.org/10.3389/fphys.2022.836480.34. Tkacs NC, Thompson HJ. From Bedside to Benchand Back Again: Research Issues in AnimalModels of Human Disease. Biol Res Nurs2006; 8: 78-88.https://doi.org/10.1177/1099800406289717.35. Dom%u00ednguez-Oliva A, Hern%u00e1ndez-%u00c1valos I,Mart%u00ednez-Burnes J, et al. The Importance ofAnimal Models in Biomedical Research:Current Insights and Applications. Animals(Basel) 2023; 13: 1223.https://doi.org/10.3390/ani13071223.36. Kiani AK, Pheby D, Henehan G, et al. Ethicalconsiderations regarding animalexperimentation. J Prev Med Hyg 2022; 63:E255-E266. https://doi.org/10.15167/2421-4248/jpmh2022.63.2S3.2768.37. Cui J, O%u2019Shea KS, Purkayastha A, et al. Fatalhaemorrhage and incomplete block toembryogenesis in mice lacking coagulationfactor V. Nature 1996; 384: 66-8.https://doi.org/10.1038/384066a0.38. Yang T, Cui J, Taylor J, et al. Rescue of FatalNeonatal Hemorrhage in Factor V DeficientMice by Low Level Transgene Expression.Thromb Haemost 2000; 83: 70-7. PMID:10669158.39. Weyand AC, Grzegorski SJ, Rost MS, et al.Analysis of factor V in zebrafishdemonstrates minimal levels needed forearly hemostasis. Blood Adv 2019; 3: 1670-80.https://doi.org/10.1182/bloodadvances.2018029066.40. Shakweer WME, Krivoruchko AY, Dessouki ShM, etal. A review of transgenic animal techniquesand their applications. J Genet Eng Biotechnol2023; 21: 55. https://doi.org/10.1186/s43141-023-00502-z.41. Birling MC, Herault Y, Pavlovic G. Modeling humandisease in rodents by CRISPR/Cas9 genomeediting. Mamm Genome 2017; 28: 291-301.https://doi.org/10.1007/s00335-017-9703-x.24. Tabibian S, Dorgalaleh A, Camire RM. CongenitalFactor V Deficiency. En: Dorgalaleh A, Ed.Congenital Bleeding Disorders. Cham:Springer International Publishing 2018; pp.201-18. Disponible en:(http://link.springer.com/10.1007/978-3-319-76723-9_8).25. Bernal S, Pelaez I, Alias L, et al. High MutationalHeterogeneity, and New Mutations in theHuman Coagulation Factor V Gene. FuturePerspectives for Factor V Deficiency UsingRecombinant and Advanced Therapies. Int JMol Sci 2021; 22: 9705.https://doi.org/10.3390/ijms22189705.26. Jain S, Acharya SS. Management of rarecoagulation disorders in 2018. Transfus ApherSci 2018; 57: 705-12.https://doi.org/10.1016/j.transci.2018.10.009.27. Heger A, Svae TE, Neisser-Svae A, et al.Biochemical quality of the pharmaceuticallylicensed plasma OctaplasLG %u00ae afterimplementation of a novel prion protein (PrPSc) removal technology and reduction of thesolvent/detergent (S/D) process time. VoxSang 2009; 97: 219-25.https://doi.org/10.1111/j.1423-0410.2009.01190.x.28. Naderi M, Tabibian S, Shamsizadeh M, et al.Miscarriage and recurrent miscarriage inpatients with congenital factor V deficiency:a report of six cases in Iran. Int J Hematol2016; 103: 673-5.https://doi.org/10.1007/s12185-016-1981-7.29. von Drygalski A, Bhat V, Gale AJ, et al. AnEngineered Factor Va Prevents BleedingInduced by Anticoagulant wt ActivatedProtein C. Doering CB, editor. PLoS ONE2014; 9: e104304.https://doi.org/10.1371/journal.pone.0104304.30. Nakamura T, Morishige S, Ozawa H, et al.Successful correction of factor V deficiencyof patient-derived iPSCs byCRISPR/Cas9-mediated gene editing.Haemophilia 2020; 26: 826-33.https://doi.org/10.1111/hae.14104.31. Sun J, Chen X, Chai Z, et al. Adeno-associatedvirus-mediated expression of activated factorV (FVa) for hemophilia phenotypic correction.Front Med (Lausanne) 2022; 9: 880763.https://doi.org/10.3389/fmed.2022.880763.42ANALESRANFwww.analesranf.comD%u00e9ficit de factor V y terapias avanzadasAntonio Liras et al.An. R.Acad. Farm.Vol. 91. n%u00ba1 (2025) %u00b7 pp. 17-44